Actinium Pharmaceuticals Logo
US00507W2061
A2QA48
ATNM

Actinium Pharmaceuticals

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 10,07 (+645,93%). A mediana é € 4,50 (+233,33%).

Comprar
  11
Manter
  0
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Actinium shows strong preclinical efficacy of ATNM-400 in NSCLC models

    Actinium presented preclinical data on ATNM-400, an Actinium-225–linked radioconjugate for non‑small cell lung cancer, at the Society of Nuclear Medicine annual meeting. In KRAS‑mutant models, ATNM-400 as monotherapy outperformed the KRAS inhibitors sotorasib and adagrasib and enhanced their tumor‑cell killing when combined. In EGFR‑mutant models, ATNM-400 achieved 75% tumor growth inhibition versus 40% for osimertinib; the combination produced complete tumor regressions in all treated mice. The target antigen was detectable in approximately 98% of NSCLC tumors, and investor assessments see upside potential for the stock despite high cash burn. » Mais em de.investing.com


  • Actinium presents preclinical data on ATNM-400 and Actimab‑A at AACR on April 21

    Actinium will present posters with unpublished preclinical data on April 21 at the AACR annual meeting for ATNM-400 (an Ac‑225 radioconjugate for solid tumors) and Actimab‑A (a therapy for AML/MDS). ATNM-400 showed activity in models of metastatic, castration‑resistant prostate cancer as well as non‑small cell lung and breast cancer; Actimab‑A data illuminate a mechanism described as “transcriptional reprogramming.” The presentations are part of the session block “Radiopharmaceutical Platforms for Theranostic Precision Oncology”; Actimab‑A is being co‑developed with the National Cancer Institute. The stock is trading near its 52‑week low and the company reports high liquidity. » Mais em de.investing.com


  • Actinium Pharmaceuticals rises after promising preclinical data on ATNM-400

    Actinium Pharmaceuticals' stock rose about 3.7% after the presentation of new preclinical data on ATNM-400 at the San Antonio Breast Cancer Symposium 2025. The Actinium-225–based antibody‑radioconjugate showed strong antitumor activity in several breast cancer models, including hormone receptor‑positive, triple‑negative and treatment‑resistant tumors, with a favorable tolerability profile. The data demonstrated irreversible double‑strand DNA breaks caused by the alpha‑emitter payload; Actinium plans to advance ATNM-400 as a monotherapy and in combinations and sees potential also in prostate and non‑small‑cell lung cancer. » Mais em de.investing.com


  • Actinium: ATNM-400 shows efficacy in preclinical models of therapy-resistant breast cancer subtypes

    Actinium presents preclinical data demonstrating a tumor-inhibiting effect of ATNM-400 in hormone receptor–positive, HER2-positive and triple-negative breast cancer models that are resistant to tamoxifen or trastuzumab. In certain models, ATNM-400 produced tumor growth inhibition of more than 100% at higher doses. The Actinium-225 antibody–radioconjugate uses alpha particles, targets proteins that are overexpressed in association with resistance, and is designed to reduce the risk of unwanted lung toxicity. The data will be presented on December 11, 2025, at the San Antonio Breast Cancer Symposium; earlier preclinical results also showed promising effects in lung and prostate cancer. » Mais em de.investing.com


  • Actinium Pharmaceuticals: shareholders elect directors and ratify audit and compensation proposals

    At the 2025 annual meeting, Ajit S. Shetty and June S. Almenoff were re-elected as Class III directors until the 2028 annual meeting. Shareholders ratified CBIZ as the independent registered public accounting firm for fiscal year 2025 and approved, in a non-binding advisory vote, the named executive officer compensation. In addition, a three-year cycle was established for future advisory votes on executive compensation. A total of 15,494,573 common shares were represented; all proposals submitted to a vote were approved. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Actinium Pharmaceuticals registou receitas de € 30,67 mi e um ganho líquido de € 24,45 mi
(EUR) junho de 2026
YoY
Receitas 30,67 mi -
Ganho bruto 30,67 mi -
Ganho líquido 24,45 mi 518,94%
EBITDA 24,66 mi 535,48%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 46,9 mi
Número de ações
31,44 mi
Máximo/mínimo de 52 semanas
€ 1,56 - € 0,67
Dividendos Não
Beta
0,02
PER (PE Ratio)
4,56
PEG (PEG Ratio)
0,02
P/VC (PB Ratio)
1,70
P/V (PS Ratio)
1,47

Perfil da empresa

A Actinium Pharmaceuticals, Inc., uma empresa biofarmacêutica em fase clínica, dedica-se ao desenvolvimento e à comercialização de terapias para transplante de medula óssea (BMT) ou um tipo de terapia celular, e para outras terapias celulares adotivas. O seu principal candidato a produto, I-131 apamistamab (Iomab-B), encontra-se num ensaio clínico pivotal de Fase III para leucemia mieloide aguda recidivante ou refratária em doentes idosos, destinado ao condicionamento para BMT; e num estudo de Fase I com uma terapia de células T CAR direcionada ao CD19, em colaboração com o Memorial Sloan Kettering Cancer Center. A empresa também disponibiliza programas de desenvolvimento clínico e pré-clínico que utilizam múltiplos isótopos, incluindo Actinium-225, Iodo-131 e Lutécio-177, direcionados a múltiplos alvos oncológicos validados, incluindo CD45, CD33, CD38, CD47, HER2 e HER3, para o condicionamento direcionado antes de terapias celulares e genéticas, como o transplante de medula óssea, e para terapias oncológicas como agentes isolados ou em combinação com outras modalidades terapêuticas. A empresa tem uma colaboração com a Astellas Pharma, Inc. para desenvolver teranósticos para tumores sólidos; com a EpicentRx, Inc., que se dedica a uma nova radioterapia direcionada de imunoterapia contra o CD47; e com a AVEO Oncology, que se dedica ao desenvolvimento de um ARC direcionado ao HER3 para tumores sólidos. A empresa foi constituída em 2000 e tem sede em Nova Iorque, Nova Iorque.

Nome
Actinium Pharmaceuticals
CEO
Sandesh C. Seth
Sede New York City, ny
EUA
Site
Indústria
Produtos químicos
Entrada em bolsa
27/12/2012
Colaboradores 27

Análise aprofundada

Símbolos de ticker

Bolsa Símbolo
AMEX
ATNM
Frankfurt
7AY1.F
Düsseldorf
7AY1.DU
🍪

Parqet  utiliza cookies. Saber mais